Requests that the FDA 1. Revise the guidance document(s) and, as necessary, associated regulations under 21 CFR Part 1271 for determining donor eligibility of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps), including reproductive tissues such as semen, to remove or substantially narrow geographic residency and travel deferrals related to variant Creutzfeldt-Jakob Disease